A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2019-04-30
Target enrollment:
Participant gender:
Summary
Epitinib (HMPL-813) is a selective EGFR tyrosine kinase inhibitor. Epitinib has demonstrated
strong inhibitory effects on multiple tumors with overexpressed EGFR or sensitive EGFR
mutations in pre-clinical setting. This first-in-human study is conducted to assess the
maximum tolerated dose (MTD) and dose-limiting toxicity(DLT), safety and tolerability,
pharmacokinetics (PK), and preliminary anti-tumor activity of Epitinib.